Goldline Pharmaceutical IPO
Goldline Pharmaceutical IPO Details
-
Open Date
12 May 2026
-
Close Date
14 May 2026
- IPO Price Range
₹ 41 to ₹43
- IPO Size
₹ 11.61 Cr
Goldline Pharmaceutical IPO Timeline
Goldline Pharmaceutical IPO Subscription Status
| Date | QIB | NII | Retail | TOTAL |
|---|---|---|---|---|
| 12-May-2026 | 1.31 | 24.46 | 34.07 | 22.35 |
| 13-May-2026 | 1.31 | 24.11 | 34.07 | 22.28 |
Last Updated: 13 May 2026 10:30 AM by 5paisa
Goldline Pharmaceuticals markets a wide range of pharmaceutical products under the “Goldline” brand, categorized into five divisions: Goldline Pharma, Cardinal, Aayushman, InLife, and Wellness, catering to multiple medical specialities including cardiology, pediatrics, orthopedics, critical care, and oncology support. The company operates through a third-party manufacturing model, where medicines are produced as per its research and specifications. All products are marketed and distributed through an extensive network of distributors, retailers, and wholesalers across the healthcare sector.
Established in: 2004
Managing Director: Mr. Amol Laxmikant Mujumdar.
Peers:
Mono Pharmacare Limited
Chandra Bhagat Pharma Limited
Goldline Pharmaceutical Objectives
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company (₹8.35 Cr )
2. General corporate purposes
Goldline Pharmaceutical IPO Size
| Types | Size |
|---|---|
| Total IPO Size | ₹11.61 Cr |
| Offer For Sale | - |
| Fresh Issue | ₹11.61 Cr |
Goldline Pharmaceutical IPO Lot Size
| Application | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 2 | 6,000 | 2,46,000 |
| Retail (Max) | 2 | 6,000 | 2,58,000 |
| S - HNI (Min) | 3 | 9,000 | 3,69,000 |
| S - HNI (Max) | 7 | 21,000 | 9,03,000 |
| B - HNI (Min) | 8 | 24,000 | 9,84,000 |
Goldline Pharmaceutical IPO Reservation
| Investors Category | Subscription (times) | Shares Offered* | Shares bid for | Total Amount (Cr.)* |
|---|---|---|---|---|
| QIB (Ex Anchor) | 1.31 | 5,40,000 | 7,05,000 | 3.03 |
| Non-Institutional Buyers | 24.11 | 3,90,000 | 94,02,000 | 40.43 |
| BNII | 21.99 | 2,58,000 | 56,73,000 | 24.39 |
| SNII | 28.25 | 1,32,000 | 37,29,000 | 16.03 |
| Individual Investors (IND category bidding for 2 Lots) | 34.07 | 9,00,000 | 3,06,60,000 | 131.84 |
| Total** | 22.28 | 18,30,000 | 4,07,67,000 | 175.30 |
*The "Shares Offered" and "Total Amount" are calculated using the upper limit of the issue price range.
**Shares allocated to anchor investors (or market makers) are excluded from the total number of shares offered.
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Revenue | 19.85 | 23.57 | 28.06 |
| EBITDA | 0.11 | 0.18 | 0.21 |
| PAT | 0.26 | 1.80 | 2.83 |
| Particulars (In ₹ Crores) | FY23 | FY24 | FY25 |
| Total Assets | 19.39 | 22.93 | 26.28 |
| Share Capital | 3.81 | 4.11 | 8.71 |
| Total Liabilities | 19.39 | 22.93 | 26.28 |
| Cash Flows (₹ Crores) | FY23 | FY24 | FY25 |
| Net Cash Generated From / (used in) Operating Activities | 2.39 | 2.92 | 2.32 |
| Net Cash Generated From / (used in) Investing Activities | -1.03 | -1.11 | 0.16 |
| Net Cash Generated From / (used in) Financing Activities | -1.44 | -1.08 | -2.03 |
| Net Increase (Decrease) in Cash and Cash Equivalents | -0.09 | 0.74 | 0.45 |
Strengths
1. Diverse portfolio covering multiple medical specialty segments
2. Strong brand presence under trusted Goldline name
3. Asset-light model reduces manufacturing infrastructure investment needs
4. Wide distributor network supports extensive market reach
Weaknesses
1. Dependence on third-party manufacturers for product supply
2. Limited control over manufacturing quality and timelines
3. Brand visibility may face intense pharmaceutical competition
4. Absence of in-house manufacturing limits operational flexibility
Opportunities
1. Growing healthcare demand increases pharmaceutical market potential
2. Expansion into rural markets through stronger distribution
3. Rising chronic diseases boost specialty medicine consumption
4. Potential partnerships with hospitals and healthcare institutions
Threats
1. Regulatory changes may impact pharmaceutical marketing operations
2. Intense competition from established pharmaceutical companies nationwide
3. Supply disruptions from third-party manufacturers affect availability
4. Price control policies may reduce profit margins
1. Diversified portfolio across high-demand therapeutic specialty segments
2. Asset-light model supports scalable and cost-efficient operations
3. Strong distributor network enhances nationwide product market reach
4. Growing pharmaceutical industry offers long-term expansion opportunities
Goldline Pharmaceuticals operates in a growing Indian pharmaceutical market driven by rising healthcare awareness, increasing chronic diseases, and expanding demand for specialty medicines. The company’s diversified portfolio across multiple therapeutic segments positions it to serve varied medical specialties effectively. Its asset-light business model and established distribution network support scalable growth opportunities. With increasing demand for affordable healthcare products and supportive industry trends, Goldline Pharmaceuticals holds strong potential for future market expansion and revenue growth.
Open Free Demat Account
Be a part of 5paisa community - The first listed discount broker of India.
By proceeding, you agree to all T&C*
FAQs
Goldline Pharmaceutical IPO opens from May 12, 2026 to May 14, 2026.
The size of Goldline Pharmaceutical IPO is ₹11.61 Cr.
The price band of Goldline Pharmaceutical IPO is fixed at ₹41 to ₹43 per share.
To apply for Goldline Pharmaceutical IPO, follow the steps given below:
● Login to your 5paisa demat account and select the issue in the current IPO section
● Enter the number of lots and the price at which you wish to apply for the Goldline Pharmaceutical. IPO.
● Enter your UPI ID and click on submit. With this, your bid will be placed with the exchange.
You will receive a mandate notification to block funds in your UPI app.
The minimum lot size of Goldline Pharmaceutical IPO is of 6,000 shares and the investment required is ₹2,46,000.
The share allotment date of Goldline Pharmaceutical IPO is May 15,2026
The Goldline Pharmaceutical IPO will likely be listed on May 19, 2026.
Cumulative Capital Pvt.Ltd is the book running lead managers for Goldline Pharmaceutical IPO.
Goldline Pharmaceutical IPO plans to utilise the raised capital from the IPO for:
1. Prepayment or repayment of all or a portion of certain outstanding borrowings availed by Company (₹8.35 Cr )
2. General corporate purposes